GlassScriptPhysician profile
Araceli Sierra
NPI 1861483000
$5,305.60
in general payments reported to CMS, 2019-2025
30 companies · $857 in 2025
The $857 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,093 · 2022: $1,033 · 2023: $1,053 · 2024: $1,270 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.77 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,150.79 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $944.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $624.33 | 2021-2025 | |
| Lilly USA, LLC | $567.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Almatica Pharma LLC | $357.02 | 2023-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Glaxosmithkline, LLC. | $247.64 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $244.93 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $137.02 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.65 | 2021-2022 | |
| Abbott Laboratories | $109.89 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $109.56 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.64 | 2022 | |
| Merck Sharp & Dohme LLC | $86.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.87 | 2021-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $53.29 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $51.43 | 2024-2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $44.66 | 2023-2024 | Rexulti |
| Amgen INC. | $30.89 | 2025 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $30.11 | 2021 | |
| Axsome Therapeutics, INC. | $29.00 | 2024 | Auvelity |
| Currax Pharmaceuticals LLC | $27.13 | 2022 | |
| Dexcom, INC. | $23.28 | 2024 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $21.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.46 | 2021 | |
| Antares Pharma, INC. | $19.98 | 2024 | Xyosted |
| Medtronic, INC. | $19.24 | 2023 | Intellis Adaptivestim |
| Si-Bone, INC. | $15.85 | 2024 | |
| Intuity Medical INC | $15.12 | 2022 | |
| Exact Sciences Corporation | $14.16 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Araceli Sierra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.